APO Research
Talk to an analyst

APO RESEARCH · REPORT

Oral Vaccine for Human

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Oral Vaccine for Human Market Outlook and Growth Opportunities 2026

30 December 2025193 pages

Choose your research edition.

Industry ResearchOral Vaccine for Human Industry Research Report 2026131 pages · $2,950 USDIndustry Growth & TrendsGlobal Oral Vaccine for Human Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Oral Vaccine for Human Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oral Vaccine for Human Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Oral Vaccine for Human Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Oral Vaccine for Human market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Oral Vaccine for Human is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Oral Vaccine for Human is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Oral Vaccine for Human is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Oral Vaccine for Human market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Oral Vaccine for Human market include Bibcol, Bio-Med, EuBiologics, Halfkin Bio-Pharmaceuticals, Panacea Biotec Ltd, PaxVax, Serum Institute, Vabiotech and Valneva, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Oral Vaccine for Human market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Oral Vaccine for Human and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Oral Vaccine for Human sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Oral Vaccine for Human market size, projected growth trends, production technologies, key applications, and end-use industries.

Oral Vaccine for Human Segment by Company

Bibcol

Bio-Med

EuBiologics

Halfkin Bio-Pharmaceuticals

Panacea Biotec Ltd

PaxVax

Serum Institute

Vabiotech

Valneva

Tiantan Biological

GSK

Merck

Sanofi

Shanghai United Cell

Lanzhou Institute

Oral Vaccine for Human Segment by Type

Cholera Vaccine

Oral Polio Vaccine

Rotavirus Vaccine

Other

Oral Vaccine for Human Segment by Application

Public

Private

Oral Vaccine for Human Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Oral Vaccine for Human status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Oral Vaccine for Human market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Oral Vaccine for Human significant trends, drivers, influence factors in global and regions.

6. To analyze Oral Vaccine for Human competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oral Vaccine for Human market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oral Vaccine for Human and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oral Vaccine for Human.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Oral Vaccine for Human market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Oral Vaccine for Human industry.

Chapter 3: Detailed analysis of Oral Vaccine for Human manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Oral Vaccine for Human in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Oral Vaccine for Human in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Oral Vaccine for Human Industry Trends Table 2. Oral Vaccine for Human Industry Drivers Table 3. Oral Vaccine for Human Industry Opportunities and Challenges Table 4. Oral Vaccine for Human Industry Restraints Table 5. Global Oral Vaccine for Human Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Oral Vaccine for Human Revenue Share by Company (2021-2026) Table 7. Global Oral Vaccine for Human Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Oral Vaccine for Human Sales Volume Share by Company (2021-2026) Table 9. Global Oral Vaccine for Human Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Oral Vaccine for Human Company Ranking, (2024-2026) & (USD Million) Table 11. Global Oral Vaccine for Human Key Company Manufacturing Base & Headquarters Table 12. Global Oral Vaccine for Human Company, Product Type & Application Table 13. Global Oral Vaccine for Human Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Oral Vaccine for Human by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Cholera Vaccine Table 18. Significant Companies of Oral Polio Vaccine Table 19. Significant Companies of Rotavirus Vaccine Table 20. Significant Companies of Other Table 21. Global Oral Vaccine for Human Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Oral Vaccine for Human Sales Volume by Type (2021-2026) & (K Units) Table 23. Global Oral Vaccine for Human Sales Volume by Type (2027-2032) & (K Units) Table 24. Global Oral Vaccine for Human Sales Volume Share by Type (2021-2026) Table 25. Global Oral Vaccine for Human Sales Volume Share by Type (2027-2032) Table 26. Global Oral Vaccine for Human Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Oral Vaccine for Human Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Oral Vaccine for Human Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Oral Vaccine for Human Sales Value Share by Type (2021-2026) Table 30. Global Oral Vaccine for Human Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Public Table 32. Significant Companies of Private Table 33. Global Oral Vaccine for Human Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Oral Vaccine for Human Sales Volume by Application (2021-2026) & (K Units) Table 35. Global Oral Vaccine for Human Sales Volume by Application (2027-2032) & (K Units) Table 36. Global Oral Vaccine for Human Sales Volume Share by Application (2021-2026) Table 37. Global Oral Vaccine for Human Sales Volume Share by Application (2027-2032) Table 38. Global Oral Vaccine for Human Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Oral Vaccine for Human Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Oral Vaccine for Human Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Oral Vaccine for Human Sales Value Share by Application (2021-2026) Table 42. Global Oral Vaccine for Human Sales Value Share by Application (2027-2032) Table 43. Global Oral Vaccine for Human Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Oral Vaccine for Human Sales by Region (2021-2026) & (K Units) Table 45. Global Oral Vaccine for Human Sales Market Share by Region (2021-2026) Table 46. Global Oral Vaccine for Human Sales by Region (2027-2032) & (K Units) Table 47. Global Oral Vaccine for Human Sales Market Share by Region (2027-2032) Table 48. Global Oral Vaccine for Human Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Oral Vaccine for Human Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Oral Vaccine for Human Sales Value Share by Region (2021-2026) Table 51. Global Oral Vaccine for Human Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Oral Vaccine for Human Sales Value Share by Region (2027-2032) Table 53. Global Oral Vaccine for Human Market Average Price (US$/Unit) by Region (2021-2026) Table 54. Global Oral Vaccine for Human Market Average Price (US$/Unit) by Region (2027-2032) Table 55. Global Oral Vaccine for Human Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Global Oral Vaccine for Human Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Oral Vaccine for Human Sales by Country (2021-2026) & (K Units) Table 58. Global Oral Vaccine for Human Sales Market Share by Country (2021-2026) Table 59. Global Oral Vaccine for Human Sales by Country (2027-2032) & (K Units) Table 60. Global Oral Vaccine for Human Sales Market Share by Country (2027-2032) Table 61. Global Oral Vaccine for Human Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Oral Vaccine for Human Sales Value Market Share by Country (2021-2026) Table 63. Global Oral Vaccine for Human Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Oral Vaccine for Human Sales Value Market Share by Country (2027-2032) Table 65. Bibcol Company Information Table 66. Bibcol Business Overview Table 67. Bibcol Oral Vaccine for Human Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. Bibcol Oral Vaccine for Human Product Portfolio Table 69. Bibcol Recent Development Table 70. Bio-Med Company Information Table 71. Bio-Med Business Overview Table 72. Bio-Med Oral Vaccine for Human Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Bio-Med Oral Vaccine for Human Product Portfolio Table 74. Bio-Med Recent Development Table 75. EuBiologics Company Information Table 76. EuBiologics Business Overview Table 77. EuBiologics Oral Vaccine for Human Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. EuBiologics Oral Vaccine for Human Product Portfolio Table 79. EuBiologics Recent Development Table 80. Halfkin Bio-Pharmaceuticals Company Information Table 81. Halfkin Bio-Pharmaceuticals Business Overview Table 82. Halfkin Bio-Pharmaceuticals Oral Vaccine for Human Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Halfkin Bio-Pharmaceuticals Oral Vaccine for Human Product Portfolio Table 84. Halfkin Bio-Pharmaceuticals Recent Development Table 85. Panacea Biotec Ltd Company Information Table 86. Panacea Biotec Ltd Business Overview Table 87. Panacea Biotec Ltd Oral Vaccine for Human Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Panacea Biotec Ltd Oral Vaccine for Human Product Portfolio Table 89. Panacea Biotec Ltd Recent Development Table 90. PaxVax Company Information Table 91. PaxVax Business Overview Table 92. PaxVax Oral Vaccine for Human Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. PaxVax Oral Vaccine for Human Product Portfolio Table 94. PaxVax Recent Development Table 95. Serum Institute Company Information Table 96. Serum Institute Business Overview Table 97. Serum Institute Oral Vaccine for Human Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Serum Institute Oral Vaccine for Human Product Portfolio Table 99. Serum Institute Recent Development Table 100. Vabiotech Company Information Table 101. Vabiotech Business Overview Table 102. Vabiotech Oral Vaccine for Human Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Vabiotech Oral Vaccine for Human Product Portfolio Table 104. Vabiotech Recent Development Table 105. Valneva Company Information Table 106. Valneva Business Overview Table 107. Valneva Oral Vaccine for Human Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Valneva Oral Vaccine for Human Product Portfolio Table 109. Valneva Recent Development Table 110. Tiantan Biological Company Information Table 111. Tiantan Biological Business Overview Table 112. Tiantan Biological Oral Vaccine for Human Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Tiantan Biological Oral Vaccine for Human Product Portfolio Table 114. Tiantan Biological Recent Development Table 115. GSK Company Information Table 116. GSK Business Overview Table 117. GSK Oral Vaccine for Human Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. GSK Oral Vaccine for Human Product Portfolio Table 119. GSK Recent Development Table 120. Merck Company Information Table 121. Merck Business Overview Table 122. Merck Oral Vaccine for Human Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. Merck Oral Vaccine for Human Product Portfolio Table 124. Merck Recent Development Table 125. Sanofi Company Information Table 126. Sanofi Business Overview Table 127. Sanofi Oral Vaccine for Human Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 128. Sanofi Oral Vaccine for Human Product Portfolio Table 129. Sanofi Recent Development Table 130. Shanghai United Cell Company Information Table 131. Shanghai United Cell Business Overview Table 132. Shanghai United Cell Oral Vaccine for Human Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 133. Shanghai United Cell Oral Vaccine for Human Product Portfolio Table 134. Shanghai United Cell Recent Development Table 135. Lanzhou Institute Company Information Table 136. Lanzhou Institute Business Overview Table 137. Lanzhou Institute Oral Vaccine for Human Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 138. Lanzhou Institute Oral Vaccine for Human Product Portfolio Table 139. Lanzhou Institute Recent Development Table 140. Key Raw Materials Table 141. Raw Materials Key Suppliers Table 142. Oral Vaccine for Human Distributors List Table 143. Oral Vaccine for Human Customers List Table 144. Research Programs/Design for This Report Table 145. Authors List of This Report Table 146. Secondary Sources Table 147. Primary Sources List of Figures Figure 1. Oral Vaccine for Human Product Image Figure 2. Global Oral Vaccine for Human Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Oral Vaccine for Human Sales Value (2021-2032) & (US$ Million) Figure 4. Global Oral Vaccine for Human Sales (2021-2032) & (K Units) Figure 5. Global Oral Vaccine for Human Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Oral Vaccine for Human Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Cholera Vaccine Image Figure 10. Oral Polio Vaccine Image Figure 11. Rotavirus Vaccine Image Figure 12. Other Image Figure 13. Global Oral Vaccine for Human Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Oral Vaccine for Human Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Oral Vaccine for Human Sales Volume Share by Type (2021-2032) Figure 16. Global Oral Vaccine for Human Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Oral Vaccine for Human Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Oral Vaccine for Human Sales Value Share by Type (2021-2032) Figure 19. Public Image Figure 20. Private Image Figure 21. Global Oral Vaccine for Human Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Oral Vaccine for Human Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Oral Vaccine for Human Sales Volume Share by Application (2021-2032) Figure 24. Global Oral Vaccine for Human Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Oral Vaccine for Human Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Oral Vaccine for Human Sales Value Share by Application (2021-2032) Figure 27. Global Oral Vaccine for Human Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 28. Global Oral Vaccine for Human Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Oral Vaccine for Human Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Oral Vaccine for Human Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Oral Vaccine for Human Sales Value (2021-2032) & (US$ Million) Figure 32. North America Oral Vaccine for Human Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Oral Vaccine for Human Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Oral Vaccine for Human Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Oral Vaccine for Human Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Oral Vaccine for Human Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Oral Vaccine for Human Sales Value (2021-2032) & (US$ Million) Figure 38. South America Oral Vaccine for Human Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Oral Vaccine for Human Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Oral Vaccine for Human Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Oral Vaccine for Human Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Oral Vaccine for Human Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Oral Vaccine for Human Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Oral Vaccine for Human Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Oral Vaccine for Human Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Oral Vaccine for Human Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Oral Vaccine for Human Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Oral Vaccine for Human Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Oral Vaccine for Human Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Oral Vaccine for Human Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Oral Vaccine for Human Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Oral Vaccine for Human Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Oral Vaccine for Human Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Oral Vaccine for Human Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Oral Vaccine for Human Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Oral Vaccine for Human Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Oral Vaccine for Human Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Oral Vaccine for Human Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Oral Vaccine for Human Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Oral Vaccine for Human Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Oral Vaccine for Human Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Oral Vaccine for Human Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Oral Vaccine for Human Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Oral Vaccine for Human Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Oral Vaccine for Human Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Oral Vaccine for Human Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Oral Vaccine for Human Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Oral Vaccine for Human Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Oral Vaccine for Human Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Oral Vaccine for Human Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Oral Vaccine for Human Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Oral Vaccine for Human Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Oral Vaccine for Human Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Oral Vaccine for Human Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Oral Vaccine for Human Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Oral Vaccine for Human Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Oral Vaccine for Human Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Oral Vaccine for Human Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Oral Vaccine for Human Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Oral Vaccine for Human Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Oral Vaccine for Human Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Oral Vaccine for Human Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Oral Vaccine for Human Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Oral Vaccine for Human Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Oral Vaccine for Human Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Oral Vaccine for Human Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Oral Vaccine for Human Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Oral Vaccine for Human Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Oral Vaccine for Human Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Oral Vaccine for Human Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Oral Vaccine for Human Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Oral Vaccine for Human Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Oral Vaccine for Human Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Oral Vaccine for Human Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Oral Vaccine for Human Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Oral Vaccine for Human Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Oral Vaccine for Human Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Oral Vaccine for Human Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Oral Vaccine for Human Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Oral Vaccine for Human Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Oral Vaccine for Human Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Oral Vaccine for Human Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Oral Vaccine for Human Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Oral Vaccine for Human Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Oral Vaccine for Human Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Oral Vaccine for Human Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Oral Vaccine for Human Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Oral Vaccine for Human Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Oral Vaccine for Human Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Oral Vaccine for Human Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Oral Vaccine for Human Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Oral Vaccine for Human Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Oral Vaccine for Human Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Oral Vaccine for Human Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Oral Vaccine for Human Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Oral Vaccine for Human Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Oral Vaccine for Human Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Oral Vaccine for Human Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Oral Vaccine for Human Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Oral Vaccine for Human Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Oral Vaccine for Human Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Oral Vaccine for Human Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Oral Vaccine for Human Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Oral Vaccine for Human Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Oral Vaccine for Human Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Oral Vaccine for Human Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Cholera Vaccine
  • Oral Polio Vaccine
  • Rotavirus Vaccine
  • Other
Applications
  • Public
  • Private
Companies covered
  • Bibcol
  • Bio-Med
  • EuBiologics
  • Halfkin Bio-Pharmaceuticals
  • Panacea Biotec Ltd
  • PaxVax
  • Serum Institute
  • Vabiotech
  • Valneva
  • Tiantan Biological
  • GSK
  • Merck
  • Sanofi
  • Shanghai United Cell
  • Lanzhou Institute

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Oral Vaccine for Human Sales Value (2021-2032)
  4. 1.2.2 Global Oral Vaccine for Human Sales Volume (2021-2032)
  5. 1.2.3 Global Oral Vaccine for Human Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Oral Vaccine for Human Market Dynamics
  1. 2.1 Oral Vaccine for Human Industry Trends
  2. 2.2 Oral Vaccine for Human Industry Drivers
  3. 2.3 Oral Vaccine for Human Industry Opportunities and Challenges
  4. 2.4 Oral Vaccine for Human Industry Restraints
3 Oral Vaccine for Human Market by Company
  1. 3.1 Global Oral Vaccine for Human Company Revenue Ranking in 2025
  2. 3.2 Global Oral Vaccine for Human Revenue by Company (2021-2026)
  3. 3.3 Global Oral Vaccine for Human Sales Volume by Company (2021-2026)
  4. 3.4 Global Oral Vaccine for Human Average Price by Company (2021-2026)
  5. 3.5 Global Oral Vaccine for Human Company Ranking (2024-2026)
  6. 3.6 Global Oral Vaccine for Human Company Manufacturing Base and Headquarters
  7. 3.7 Global Oral Vaccine for Human Company Product Type and Application
  8. 3.8 Global Oral Vaccine for Human Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Oral Vaccine for Human Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Oral Vaccine for Human Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Oral Vaccine for Human Market by Type
  1. 4.1 Oral Vaccine for Human Type Introduction
  2. 4.1.1 Cholera Vaccine
  3. 4.1.2 Oral Polio Vaccine
  4. 4.1.3 Rotavirus Vaccine
  5. 4.1.4 Other
  6. 4.2 Global Oral Vaccine for Human Sales Volume by Type
  7. 4.2.1 Global Oral Vaccine for Human Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Oral Vaccine for Human Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Oral Vaccine for Human Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Oral Vaccine for Human Sales Value by Type
  11. 4.3.1 Global Oral Vaccine for Human Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Oral Vaccine for Human Sales Value by Type (2021-2032)
  13. 4.3.3 Global Oral Vaccine for Human Sales Value Share by Type (2021-2032)
5 Oral Vaccine for Human Market by Application
  1. 5.1 Oral Vaccine for Human Application Introduction
  2. 5.1.1 Public
  3. 5.1.2 Private
  4. 5.2 Global Oral Vaccine for Human Sales Volume by Application
  5. 5.2.1 Global Oral Vaccine for Human Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Oral Vaccine for Human Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Oral Vaccine for Human Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Oral Vaccine for Human Sales Value by Application
  9. 5.3.1 Global Oral Vaccine for Human Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Oral Vaccine for Human Sales Value by Application (2021-2032)
  11. 5.3.3 Global Oral Vaccine for Human Sales Value Share by Application (2021-2032)
6 Oral Vaccine for Human Regional Sales and Value Analysis
  1. 6.1 Global Oral Vaccine for Human Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Oral Vaccine for Human Sales by Region (2021-2032)
  3. 6.2.1 Global Oral Vaccine for Human Sales by Region: 2021-2026
  4. 6.2.2 Global Oral Vaccine for Human Sales by Region (2027-2032)
  5. 6.3 Global Oral Vaccine for Human Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Oral Vaccine for Human Sales Value by Region (2021-2032)
  7. 6.4.1 Global Oral Vaccine for Human Sales Value by Region: 2021-2026
  8. 6.4.2 Global Oral Vaccine for Human Sales Value by Region (2027-2032)
  9. 6.5 Global Oral Vaccine for Human Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Oral Vaccine for Human Sales Value (2021-2032)
  12. 6.6.2 North America Oral Vaccine for Human Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Oral Vaccine for Human Sales Value (2021-2032)
  15. 6.7.2 Europe Oral Vaccine for Human Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Oral Vaccine for Human Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Oral Vaccine for Human Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Oral Vaccine for Human Sales Value (2021-2032)
  21. 6.9.2 South America Oral Vaccine for Human Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Oral Vaccine for Human Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Oral Vaccine for Human Sales Value Share by Country, 2025 VS 2032
7 Oral Vaccine for Human Country-level Sales and Value Analysis
  1. 7.1 Global Oral Vaccine for Human Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Oral Vaccine for Human Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Oral Vaccine for Human Sales by Country (2021-2032)
  4. 7.3.1 Global Oral Vaccine for Human Sales by Country (2021-2026)
  5. 7.3.2 Global Oral Vaccine for Human Sales by Country (2027-2032)
  6. 7.4 Global Oral Vaccine for Human Sales Value by Country (2021-2032)
  7. 7.4.1 Global Oral Vaccine for Human Sales Value by Country (2021-2026)
  8. 7.4.2 Global Oral Vaccine for Human Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Oral Vaccine for Human Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Oral Vaccine for Human Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Oral Vaccine for Human Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Oral Vaccine for Human Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Oral Vaccine for Human Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Oral Vaccine for Human Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Oral Vaccine for Human Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Oral Vaccine for Human Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Oral Vaccine for Human Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Oral Vaccine for Human Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Oral Vaccine for Human Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Oral Vaccine for Human Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Oral Vaccine for Human Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Oral Vaccine for Human Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Oral Vaccine for Human Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Oral Vaccine for Human Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Oral Vaccine for Human Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Oral Vaccine for Human Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Oral Vaccine for Human Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Oral Vaccine for Human Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Oral Vaccine for Human Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Oral Vaccine for Human Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Oral Vaccine for Human Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Oral Vaccine for Human Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Oral Vaccine for Human Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Oral Vaccine for Human Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Oral Vaccine for Human Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Oral Vaccine for Human Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Oral Vaccine for Human Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Oral Vaccine for Human Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Oral Vaccine for Human Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Oral Vaccine for Human Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Oral Vaccine for Human Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Oral Vaccine for Human Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Oral Vaccine for Human Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Oral Vaccine for Human Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Oral Vaccine for Human Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Oral Vaccine for Human Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Oral Vaccine for Human Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Oral Vaccine for Human Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Oral Vaccine for Human Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Oral Vaccine for Human Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Oral Vaccine for Human Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Oral Vaccine for Human Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Oral Vaccine for Human Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Oral Vaccine for Human Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Oral Vaccine for Human Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Oral Vaccine for Human Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Oral Vaccine for Human Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Oral Vaccine for Human Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Oral Vaccine for Human Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Oral Vaccine for Human Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Oral Vaccine for Human Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Oral Vaccine for Human Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Oral Vaccine for Human Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Oral Vaccine for Human Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Oral Vaccine for Human Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Oral Vaccine for Human Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Oral Vaccine for Human Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Oral Vaccine for Human Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Oral Vaccine for Human Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Oral Vaccine for Human Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Oral Vaccine for Human Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Oral Vaccine for Human Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Oral Vaccine for Human Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Oral Vaccine for Human Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Oral Vaccine for Human Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Oral Vaccine for Human Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Oral Vaccine for Human Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Oral Vaccine for Human Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Oral Vaccine for Human Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Oral Vaccine for Human Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Oral Vaccine for Human Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Oral Vaccine for Human Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Oral Vaccine for Human Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Oral Vaccine for Human Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Oral Vaccine for Human Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Oral Vaccine for Human Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Oral Vaccine for Human Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Oral Vaccine for Human Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Oral Vaccine for Human Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Oral Vaccine for Human Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Oral Vaccine for Human Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Oral Vaccine for Human Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Bibcol
  2. 8.1.1 Bibcol Company Information
  3. 8.1.2 Bibcol Business Overview
  4. 8.1.3 Bibcol Oral Vaccine for Human Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Bibcol Oral Vaccine for Human Product Portfolio
  6. 8.1.5 Bibcol Recent Developments
  7. 8.2 Bio-Med
  8. 8.2.1 Bio-Med Company Information
  9. 8.2.2 Bio-Med Business Overview
  10. 8.2.3 Bio-Med Oral Vaccine for Human Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Bio-Med Oral Vaccine for Human Product Portfolio
  12. 8.2.5 Bio-Med Recent Developments
  13. 8.3 EuBiologics
  14. 8.3.1 EuBiologics Company Information
  15. 8.3.2 EuBiologics Business Overview
  16. 8.3.3 EuBiologics Oral Vaccine for Human Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 EuBiologics Oral Vaccine for Human Product Portfolio
  18. 8.3.5 EuBiologics Recent Developments
  19. 8.4 Halfkin Bio-Pharmaceuticals
  20. 8.4.1 Halfkin Bio-Pharmaceuticals Company Information
  21. 8.4.2 Halfkin Bio-Pharmaceuticals Business Overview
  22. 8.4.3 Halfkin Bio-Pharmaceuticals Oral Vaccine for Human Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Halfkin Bio-Pharmaceuticals Oral Vaccine for Human Product Portfolio
  24. 8.4.5 Halfkin Bio-Pharmaceuticals Recent Developments
  25. 8.5 Panacea Biotec Ltd
  26. 8.5.1 Panacea Biotec Ltd Company Information
  27. 8.5.2 Panacea Biotec Ltd Business Overview
  28. 8.5.3 Panacea Biotec Ltd Oral Vaccine for Human Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Panacea Biotec Ltd Oral Vaccine for Human Product Portfolio
  30. 8.5.5 Panacea Biotec Ltd Recent Developments
  31. 8.6 PaxVax
  32. 8.6.1 PaxVax Company Information
  33. 8.6.2 PaxVax Business Overview
  34. 8.6.3 PaxVax Oral Vaccine for Human Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 PaxVax Oral Vaccine for Human Product Portfolio
  36. 8.6.5 PaxVax Recent Developments
  37. 8.7 Serum Institute
  38. 8.7.1 Serum Institute Company Information
  39. 8.7.2 Serum Institute Business Overview
  40. 8.7.3 Serum Institute Oral Vaccine for Human Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Serum Institute Oral Vaccine for Human Product Portfolio
  42. 8.7.5 Serum Institute Recent Developments
  43. 8.8 Vabiotech
  44. 8.8.1 Vabiotech Company Information
  45. 8.8.2 Vabiotech Business Overview
  46. 8.8.3 Vabiotech Oral Vaccine for Human Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Vabiotech Oral Vaccine for Human Product Portfolio
  48. 8.8.5 Vabiotech Recent Developments
  49. 8.9 Valneva
  50. 8.9.1 Valneva Company Information
  51. 8.9.2 Valneva Business Overview
  52. 8.9.3 Valneva Oral Vaccine for Human Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Valneva Oral Vaccine for Human Product Portfolio
  54. 8.9.5 Valneva Recent Developments
  55. 8.10 Tiantan Biological
  56. 8.10.1 Tiantan Biological Company Information
  57. 8.10.2 Tiantan Biological Business Overview
  58. 8.10.3 Tiantan Biological Oral Vaccine for Human Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Tiantan Biological Oral Vaccine for Human Product Portfolio
  60. 8.10.5 Tiantan Biological Recent Developments
  61. 8.11 GSK
  62. 8.11.1 GSK Company Information
  63. 8.11.2 GSK Business Overview
  64. 8.11.3 GSK Oral Vaccine for Human Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 GSK Oral Vaccine for Human Product Portfolio
  66. 8.11.5 GSK Recent Developments
  67. 8.12 Merck
  68. 8.12.1 Merck Company Information
  69. 8.12.2 Merck Business Overview
  70. 8.12.3 Merck Oral Vaccine for Human Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Merck Oral Vaccine for Human Product Portfolio
  72. 8.12.5 Merck Recent Developments
  73. 8.13 Sanofi
  74. 8.13.1 Sanofi Company Information
  75. 8.13.2 Sanofi Business Overview
  76. 8.13.3 Sanofi Oral Vaccine for Human Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Sanofi Oral Vaccine for Human Product Portfolio
  78. 8.13.5 Sanofi Recent Developments
  79. 8.14 Shanghai United Cell
  80. 8.14.1 Shanghai United Cell Company Information
  81. 8.14.2 Shanghai United Cell Business Overview
  82. 8.14.3 Shanghai United Cell Oral Vaccine for Human Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Shanghai United Cell Oral Vaccine for Human Product Portfolio
  84. 8.14.5 Shanghai United Cell Recent Developments
  85. 8.15 Lanzhou Institute
  86. 8.15.1 Lanzhou Institute Company Information
  87. 8.15.2 Lanzhou Institute Business Overview
  88. 8.15.3 Lanzhou Institute Oral Vaccine for Human Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Lanzhou Institute Oral Vaccine for Human Product Portfolio
  90. 8.15.5 Lanzhou Institute Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Oral Vaccine for Human Value Chain Analysis
  2. 9.1.1 Oral Vaccine for Human Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Oral Vaccine for Human Sales Mode & Process
  6. 9.2 Oral Vaccine for Human Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Oral Vaccine for Human Distributors
  9. 9.2.3 Oral Vaccine for Human Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst